跳至主要内容
临床试验/NCT00301041
NCT00301041已完成1 期

The Relationship Between Plasma Transforming Growth Factor-beta 1 (TGF-β) and Fractionation in Radiotherapy for Breast Cancer: A Randomized Study

University of California, San Francisco1 个研究点 分布在 1 个国家目标入组 20 人开始时间: 2004年4月1日最近更新:
适应症

试验速览

阶段
1 期
状态
已完成
入组人数
20
试验地点
1

研究概览

简要总结

RATIONALE: Radiation therapy uses high-energy x-rays to kill tumor cells. Giving radiation therapy in different ways may kill more tumor cells.

PURPOSE: This randomized clinical trial is studying the side effects and best way to give radiation therapy and to see how well it works in treating patients with invasive breast cancer.

详细描述

OBJECTIVES:

Primary

  • Compare the ratio between post- and pre-treatment plasma transforming growth factor-beta 1 (TGF-β) in women with invasive breast cancer undergoing hypofractionated radiotherapy vs standard-fractionated external-beam radiotherapy.

Secondary

  • Establish longitudinal serum and plasma biorepository for retrospective evaluation of TGF-β and other biomarkers with special relevance to radiation response.
  • Correlate pre-treatment plasma TGF-β levels with clinical fibrosis development.

研究设计

研究类型
Interventional
分配方式
Randomized
干预模型
Parallel
主要目的
Treatment
盲法
None

入排标准

年龄范围
18 Years 至 —(Adult, Older Adult)
性别
All
接受健康志愿者
否

入选标准

  • •DISEASE CHARACTERISTICS:
  • •Histologically confirmed invasive breast cancer
  • •Underwent lumpectomy (breast-preserving surgery) with or without adjuvant chemotherapy within the past 12 weeks
  • •Histologically negative surgical margins (i.e., no tumor on ink)
  • •Candidates for postoperative breast radiotherapy
  • •Determined not to need radiotherapy to regional nodes (e.g., third supraclavicular field)
  • •Hormone receptor status not specified
  • •PATIENT CHARACTERISTICS:
  • •Menopausal status not specified
  • •Not pregnant or nursing
  • •Negative pregnancy test
  • •Fertile patients must use effective contraception
  • •No history of scleroderma or systemic lupus erythematosis
  • •No other prior or concurrent malignancy except nonmelanoma skin cancer or carcinoma in situ of the cervix
  • •PRIOR CONCURRENT THERAPY:
  • •See Disease Characteristics
  • •No prior breast radiotherapy

排除标准

  • 未提供

研究者

申办方类型
Other
责任方
Sponsor

研究点 (1)

Loading locations...

相似试验